A glance at what’s happening in the world of technology.
1. Tiny implant for rare, sight-robbing disease shows efficacy
The first Food and Drug Administration-approved treatment for a rare, progressive retinal neurovascular and glial degenerative disease has been found to demonstrate efficacy in the latest round of trials.
Macular telangiectasia type 2 (MacTel) produces a macular photoreceptor atrophy and loss of central vision in patients.
The study, published in NEJM Evidence, investigated the efficacy and safety of revakinagene taroretcel (NT-501) in two phase III trials. These found that NT-501 resulted in a statistically significant reduced progression of ellipsoid zone area loss.
The researchers concluded that the implant may provide a protected environment for retinal pigment epithelial cells to survive and secrete therapeutic levels of ciliary neurotrophic factor.
Sign in to continue
Not already a member of the College?
Start enjoying the benefits of College membership today. Take a look at what the College can offer you and view our membership categories and rates.
The Government’s 10-Year Health Plan is a crucial chance to expand and strengthen primary eye care by cutting hospital pressure and tackling inequalities in access across England.